- Joined
- 12 January 2008
- Posts
- 7,154
- Reactions
- 17,710
From AFR article: [Author: Joshua Peach]
"Shares in ResMed plunged more than 13 per cent on Monday after results over the weekend from a weight-loss drug trial resurfaced investor doubts about the sleep apnoea treatment provider’s key market."
Eli-Lilly reporting that its weight-loss drug, tirzepatide reduced the severity of sleep apnoea in 62% of the trial patients.
"Shares in ResMed plunged more than 13 per cent on Monday after results over the weekend from a weight-loss drug trial resurfaced investor doubts about the sleep apnoea treatment provider’s key market."
Eli-Lilly reporting that its weight-loss drug, tirzepatide reduced the severity of sleep apnoea in 62% of the trial patients.